Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on June 08, 2018, 03:36:39 pm
-
Among Europeans, the introduction of highly effective direct-acting antivirals (DAAs) to treat hepatitis C virus (HCV) has reduced the proportion of those receiving a liver transplant as a result of the virus, aidsmap reports.
Researchers analyzed data from the European Liver Transplant Registry. Between January 2007 and June 2017, 36,382 people received a liver transplant as a result of HCV, hepatitis B virus (HBV) or alcoholic or non-alcoholic steatohepatitis (NASH). They broke down the data into two eras: 2007 to 2010, when hep C was treated with interferon, and 2014 to 2017, during which interferon-free DAA treatment became dominant. (During the interim period, DAAs were on the market but commonly used with interferon.)
Read more...
https://www.hepmag.com/article/new-hepatitis-c-drugs-reduced-need-liver-transplants